Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Clinical trial NCT04812535 · TERMINATED

Trial details

NCT number: NCT04812535
Sponsor: InflaRx GmbH
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

SCC - Squamous Cell Carcinoma of Skin

Start date: 2021-03-31
Primary completion: 2024-06-04
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.